Publications by authors named "J Moppett"
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg IV) plus backbone chemotherapy in children with relapsed/refractory B-cell ALL (n = 7) after ≥2 relapses, and children and young adults with T-cell ALL (children, n = 24; young adults, n = 5) or LL (n = 10) after first relapse. The primary end point was complete response (CR) in the B-cell ALL (end of cycle 2) and T-cell ALL (end of cycle 1) cohorts, after which patients could proceed off study to allogeneic hematopoietic stem cell transplant (HSCT).
View Article and Find Full Text PDFArticle Synopsis
- - This study investigated the effects of hematopoietic stem cell transplantation (HSCT) in children using either bone marrow (BM) or peripheral blood stem cells (PBSC) after conditioning with alemtuzumab, focusing on the risks of severe acute and chronic graft-versus-host disease (GVHD).
- - In a multicenter analysis of 397 children, it was found that the PBSC group had a higher incidence of grade II-IV acute GVHD (31%) compared to the BM group (19%), but the incidence of severe (grade III-IV) GVHD was similar for both groups.
- - The research suggested that using alemtuzumab for T cell depletion and specific prophylaxis strategies may reduce GVHD
Purpose: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant.
Methods: Data were collected for consecutive CYP (age 1-24 years) with Philadelphia chromosome-positive or Philadelphia chromosome-negative B-ALL who received Blina as first-line therapy. Blina was given as replacement for postremission intensive chemotherapy to patients with chemotherapy intolerance or resistance.
Article Synopsis
- - The study investigates the mechanisms behind Shiga toxin-producing E. coli hemolytic uremic syndrome (STEC-HUS), a leading cause of acute kidney injury in children, revealing that the glomerular microvasculature is particularly vulnerable to damage from systemic Stx infection.
- - Researchers engineered mice to express the Stx receptor in kidney cells and found that exposure led to reduction of a crucial growth factor (VEGF-A), causing more damage via complement pathway activation.
- - The findings suggest that early intervention using a C5 inhibitor could be a promising treatment to mitigate the effects of STx-induced HUS, enhancing understanding of the disease's targeting of the kidneys.